Relationship between use of selective serotonin reuptake inhibitors and irritable bowel syndrome: A population-based cohort study

Table 2 Comparisons of the incidence of irritable bowel syndrome by age, gender, comorbidity and drug use

Variable	Events	PT	Rate1	HR2	(95%CI)	P value
Sex
Female	414	335363	1.23	1.00	(reference)
Male	300	233656	1.28	1.05	(0.91-1.23)	0.495
Age, yr
< 20	13	43139	0.30	1.00	(reference)
20-29	47	91408	0.51	1.62	(0.87-3.01)	0.128
30-39	93	110721	0.84	2.52	(1.40-4.55)	0.002
40-49	153	113198	1.35	3.94	(2.22-7.02)	< 0.001
50-59	133	80752	1.65	4.56	(2.54-8.17)	< 0.001
≥ 60	275	129801	2.12	5.57	(3.12-9.92)	< 0.001
Comorbidity (yes vs no)
Diabetes mellitus	113	55858	2.02	0.93	(0.74-1.17)	0.549
Hypertension	269	129073	2.08	1.06	(0.87-1.28)	0.576
Hyperlipidemia	175	84352	2.07	1.07	(0.88-1.31)	0.482
Colorectal cancer	5	1527	3.27	1.48	(0.61-3.58)	0.386
Major depressive disorder	67	30292	2.21	1.19	(0.90-1.57)	0.217
Anxiety disorder	220	96735	2.27	1.33	(1.11-1.59)	0.002
Bipolar disorder	5	2435	2.05	1.03	(0.42-2.52)	0.820
Anti-psychotics
No	630	535264	1.18	1.00	(reference)
Yes	84	33755	2.49	1.18	(0.92-1.50)	0.193
SSRIs
No	478	460307	1.04	1.00	(reference)
Yes	236	108713	2.17	1.74	(1.44-2.10)	< 0.001

¹Per 1000 person-years;

²Adjusted by age, sex, urbanization, family income, area of residence, occupation, anti-psychotics and the comorbidities listed in Table 1. IBS: Irritable bowel syndrome; SSRIs: Selective serotonin reuptake inhibitors.